ABSTRACT Newcastle disease is still causing huge economic losses and devastating outbreaks in poultry flocks despite implementation of extensive vaccination programs. Five commercial broiler chicken groups were established as G1 (non-vaccinated, non-challenged group) and G2 (non-vaccinated, challenged group), and 3 vaccinated challenged groups as G3 (vaccinated with heterologous inactivated Newcastle disease virus (NDV) genotype II (NDV II) vaccine), G4 (vaccinated with homologous inactivated NDV genotype VII (NDV VII) vaccine), and G5 (vaccinated with bivalent (heterologous inactivated NDV II plus H5) vaccine) were used. Challenge test was done using a velogenic NDV genotype VII (vNDV VII) at 28-d olds. Respiratory signs, greenish diarrhea, and obvious postmortem lesions of vNDV VII appeared in all the challenged birds whether vaccinated or not. In addition, the mortality rate decreased from 93.3% in G2 to 46.7%, 53.3%, and 66.7% in G4, G5, and G3, respectively. Overall, 2 wk postchallenge; body weight loss (%) had increased mainly in G2, with some improvement in chickens in G4 followed by G5 and chickens of G3 showed the least improvement. At 28 d (day of challenge), the highest hemagglutination inhibition values were 4.3 and 5.4 log2 in chickens in G4 and G5, respectively, which increased in all groups after the challenge. Cytokine (IL-6 and IFN-γ) levels were significantly higher (P < 0.05) in the vaccinated groups than that in the non-vaccinated group, especially in G5. Viral shedding in the trachea was higher than that in the cloacal swabs in all vaccinated and nonvaccinated challenged groups with peak shedding on the 6th day post challenge for both swabs, and the lowest viral shedding titers were observed in chickens in G5. Therefore, the use of homologous genotype NDV with inactivated vaccine conferred a higher clinical protection in terms of body weight loss and mortality against vNDV VII challenge in broiler chickens; however, the heterologous vaccine used in G5 induced the highest cell-mediated immune response and hemagglutination inhibition titers with the lowest viral shedding titer.
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INTRODUCTION
Newcastle disease (ND) is an international problem for endemic countries worldwide owing to not only high mortality rates that can reach 100%, but also impaired weight gain and feed conversion rates, and decreases in egg production, fertility, and hatchability. This disease is caused by the Newcastle disease virus (NDV), an C 2018 Poultry Science Association Inc. Received April 6, 2018. Accepted November 23, 2018. 1 Corresponding authors: ahmed.elbestawy@vetmed.dmu.edu.eg (ARE); aswelum@ksu.edu.sa (AAS) avian paramyxovirus-1 belonging to genus Avulavirus of family Paramyxoviridae (Hines and Miller, 2012) .
The NDV RNA genome is composed of 6 genes, 3-NP-P-M-F-HN-L-5, encoding 6 major structural proteins; the fusion protein together with hemagglutininneuraminidase is involved in the process of viral attachment and fusion and subsequent release of progeny virions from the infected cells and also in the induction of virus-neutralizing antibody responses (Seal et al., 2000; Miller and Koch, 2013) . Moreover, the full nucleotide sequence of the fusion gene is used to classify NDV strains into 9 genotypes in class I and XVIII (I to XVIII) genotypes in class II. However, all 2000 these strains are included within one serotype (Snoeck et al., 2013) .
The sequence of the fusion protein of NDV at the cleavage site is an indicator of virulent strains that have, at positions 113 to 116, 3 or more basic amino acids with a phenylalanine at position 117, while that of the avirulent viruses contains less than 2 basic amino acids with leucine at position 117 (OIE, 2012) . The avirulent virus (mostly used in vaccines) may become virulent upon mutation of the cleavage site of the fusion protein gene (Miller et al., 2015) .
Therefore, clinical signs of the disease vary from acute lethal infection with high mortality to asymptomatic based on the pathotype of the infected strain of NDV, which is either virulent (velogenic, mesogenic, and lentogenic) or avirulent (asymptomatic) (Wakamatsu et al., 2006) .
Both humoral and cell-mediated immunity (CMI) have been induced by NDV infection where virus neutralizing or hemagglutination-inhibition antibodies are essential to protect against clinical signs but cannot prevent viral shedding. T cells have been found to be necessary for the clearance of NDV and various cytokines have been included in viral defense mechanism such as INF-γ that are a good measure of cell-mediated immunity in chickens (Lambrecht et al., 2004) .
The more prevalent NDV genotype circulating in Asia, the Middle East and South Africa (Bogoyavlenskiy et al., 2009) , South America (Miller and Koch, 2013) , and Europe (Herczeg et al., 1999) is the genotype VII strain that is responsible for the fourth and latest pandemic that started in the late 1980s.
ND outbreaks are occurring frequently and the most recent NDV isolates from different outbreaks have been classified into class II genotype VII, sub genotype d (lineage 5 sub lineage d) since 2011 (first record of isolation), even in vaccinated farms (Radwan et al., 2013; Abdel-Glil et al., 2014; Awad et al., 2015; Hassan et al., 2016) .
The question arises as to why we cannot protect against ND via intensive vaccine programs. Genetic divergence between the wild virus and vaccine strain might be a factor that has translated to poor crossimmunity between the vaccine and field challenge virus strains (Yi et al., 2011) . Furthermore, Hu et al. (2011) stressed that genotype matched vaccines that reduce viral shedding should be an essential component of disease control. The NDRL0901 strain might be a suitable NDV live vaccine candidate for use in hatcheries as well as farms, which is safe while maintaining solid immunity under a combined SP and DW vaccination program (Kim et al., 2016) . The application of the live LaSota strain NDV vaccine as the primary immunization has a negative effect on the development of adaptive immunity in broilers; however, its use after the level of maternal antibodies decay results in a robust antigen-specific humoral immune response (Martinez et al., 2018) .
From the principle that all NDV strains belong to a single serotype, the aim of the present study was to determine whether the use of a classical vaccine of different genotype (genotype II) or the same genotype (genotype VII) stimulates higher humoral and cellular immune response against challenge with the recent isolate of genotype VII to protect from clinical disease, mortality, and viral shedding in the field. Therefore, in the present study we assessed the protection of broiler chickens vaccinated with inactivated NDV vaccines of different genotypes (II and VII) and challenged with a recent isolate of NDV, genotype VII.
MATERIALS AND METHODS

Experimental Design
The present study was carried out according to the recommendations of the Committee on the Ethics of Animal Experiments of Alexandria University, Egypt. All procedures and experiments complied with the guidelines and were approved by the Local Ethic Commission of the Animal Experiments of Alexandria University with respect to animal experimentation and care of animals under study. All efforts were made to minimize suffering.
Seventy-five 1-d-old commercial broiler chickens (Cobb 500) supplied from a local hatchery were identified by wing tags and divided randomly after arrival into 5 groups (n = 15 with 3 replicates in each group n = 5) as follows: non-vaccinated and non-challenged G1 (negative control) and non- 
Challenge Virus
The ND challenge virus was isolated in 2014 from a vaccinated broiler farm in Egypt and classified as virulent NDV genotype VII (vNDV VII) (based on the sequence analysis of the F cleavage site and intracerebral pathogenicity index of 1.7) and registered in GenBank with accession no. KY652737.
The virus was propagated in 9 to 11-d-old SPF embryos by allantoic sac inoculation and stored at −80
• C until subsequent analysis (Terregino and Capua, 2009) . The virus challenge dose was calculated based on the method described by Reed and Muench (1938) , obtaining 10 6.3 EID50/100 μL/bird via eye drop and 50 μL each by intranasal routes.
Birds in G2, G3, G4, and G5 were challenged at 28 d [21 d post vaccination (dpv)]; whereas, birds in G1 (negative control) were sham challenged with 50 μL sterile PBS via eye drop and intranasal routes.
Mortality Rate, Clinical Signs, Post-Mortem Lesions and Bird Performance
Mortality rate and clinical signs (mainly respiratory signs as conjunctivitis, swollen head, sneezing, rales, and nasal discharge; enteric signs as greenish diarrhea and nervous signs as torticollis and recumbency) were followed daily for 14 d post-challenge (dpc) and dead birds were examined for post-mortem (PM) lesions as congested pectoral muscles, congestion and exudate in tracheal mucosa, proventricular hemorrhages, intestinal ulcers, and ileocecal tonsil's hemorrhages (OIE., 2012). Broiler performance was evaluated at 1 and 2 wk postchallenge (wpc) via body weight loss (%) in survivor birds of challenged groups G2, G3, G4, and G5 (assuming that the weight was 100% in control G1) using SPSS statistical analysis program.
Serology
Serum samples were collected randomly from 10 birds in all groups just before vaccination to determine the level of maternal antibodies. Additionally, 8 serum samples were collected from each group weekly from the first week of age until the end of the experiment at 42-d old for the hemagglutination inhibition (HI) test. The serum IgG level of the NDV was determined by HI and cross HI tests in U-bottom microtiter plates using 4 HA units of LaSota and genotype VII strains, and HI titers equal to or greater than 1/16 (2 4 ) were considered positive (OIE, 2012) .
The INF-γ assay was performed on serum samples at 21 st dpv (28-d old day of challenge) by the immunoenzymatical assay based on the ELISA manufacturer's protocol (Novatein Bio, Massachusetts, United States). ELISA plates were coated with the standard preparation for INF-γ at concentrations of 0, 6.25, 12.5, 25, 50, 100, and 200 pg/mL. Optical density (OD) was measured at a wavelength of 450 nm and interferon concentrations were calculated from the standard curve using a software product (Karakolev et al., 2015) .
Interleukin-6 (IL-6) was determined at 21 st dpv using Sandwich-ELISA where the Micro-ELISA plate provided was pre-coated with antibody specific to chicken IL-6. Optical density was measured spectrophotometrically at a wavelength of 450 nm. The concentration of IL-6 in the sample was calculated by comparing the OD of the sample to the standard curve (pg/mL), based on methodology described by (Helle et al., 1991) .
RNA Extraction and Real Time Polymerase Chain Reaction (rRT-PCR) for Viral Shedding Titers
Tracheal and cloacal swabs from all birds in each group (3 sample pools or group) were collected at 2, 6, and 9 dpc for viral shedding detection and quantification. Swabs were placed into 1.5 mL of antibiotic PBS (20 μg gentamicin and 1000 penicillin G units/mL) and centrifuged at 3000 × g for 10 min for virus clarification and stored at −80
• C until subsequent analysis. RNA was extracted from 200 μL of the collected tracheal and cloacal swab fluid using Thermo Scientific Gene JET Viral DNA and RNA Extraction Kits, United States, following the manufacturer's recommended procedures. The amplification process was performed by Stratagene Real Time PCR using Thermo Scientific master mix kits.
Primers and probes targeting fusion protein gene amplification were used based on methodology described by AlHabeeb et al. (2013) , following their steps of the cycling conditions.
Statistical Analysis
Statistical measurements were taken using the SPSS programming tool (IBM SPSS. 20, Coppell, TX, United States) by one-way analysis of variance and Duncan's multiple range tests. Data were obtained for body weight loss, HI assay, cytokines analysis, and rRT-PCR titer results. All declarations of significance depended on P < 0.05.
RESULTS
Mortality rate, Clinical Signs and PM Lesions after NDV Genotype VII Challenge
The mortality rate was 93.3% (n = 14/15 birds) in G2, which reduced to 66.7% (n = 10/15), 46.7% (n = 7/15), and 53.3% (n = 8/15) in G3, G4, and G5, respectively (Figure 1 ). All mortalities occurred on the fifth and sixth dpc.
All birds either vaccinated or not and challenged with vNDV VII appeared depressed with conjunctivitis, swollen head, sneezing, rales, and nasal discharge from second to sixth dpc. In addition, greenish diarrhea was observed in G2 and G3 birds. Nervous signs (e.g., torticollis ( Figure 2 ) and recumbency) appeared at eighth dpc in 3/5 of survived birds in G3 only as birds in G2 had dead all by sixth dpc and didn't notice in the other 2 chicken groups (G4 and G5) ( Table 1) .
Post-mortem examination of the dead birds in the vaccinated as well as in the non-vaccinated challenged groups (G2 to 5) revealed congested pectoral muscles, congestion and exudate in tracheal mucosa, hemorrhage on tips of proventriculus, ulcers in the small intestine, hemorrhages in ileocecal tonsils, and congested brain ( Figure 2 and Table 1 ). All birds in the negative control group (G1) appeared normal without mortality during the entire experimental period.
Body Weight Loss (%)
The percentage of loss was significantly higher (P < 0.05) in survivor birds of G2 during the first and second wpc than in the other 3 bird groups (G3, G4, and G5). Birds in G4 (vaccinated with homologous genotype VII vaccine) had the least BWG loss % (P < 0.05) as 18.62% and 15.61% on the first and second wpc, respectively (Figure 3 ).
Immune Response of Experimental Birds
HI and Cross HI tests Homologous (NDV genotype VII) and heterologous (laSota) antigens for the challenge virus were used to perform HI and cross HI tests (4 HA unit) on serum samples.
During the first week of age, serum samples showed HI geometric mean NDV antibody titer of 7.9 log 2 . Using laSota Ag, the titers were under the protective level (2 4 ) in all groups during the third and fourth weeks of age of the birds (2 and 3 wpv in G3, G4, and G5), at which the titers increased significantly (P < 0.05) over the protective titer in G5 (5.4 log 2 ), and the titers increased after challenge in all the groups with higher increases in G5 than in other groups (Figure 4) . Cross HI (using NDV VII Ag) in the first and second wpc resulted in a lower geometric mean in all groups with a range of difference of 1.7 to 3.8 log 2 , which was lower than the titers obtained using laSota Ag at the same age. The titers were statistically significant (P < 0.05) in fifth wpv as 12, 11.8, and 10.6 log 2 and sixth wpv as 12, 12, and 9.5 log 2 in G2, G3, and G4, respectively, which were also higher than titers using laSota Ag at the same age ( Figure 5 ).
Cytokines
IFN-γ and IL-6 measured at 28-d-old birds (21 st dpv) from G1, G3, G4, and G5 by ELISA revealed that the levels of both parameters were significantly higher (P < 0.05) in the vaccinated groups (G3, G4, and G5) than this in the non-vaccinated group (G1), especially in G5 (Figure 6 ). Figure 4 . HI test results (log 2 ) using laSota antigen at weekly interval (first to sixth weeks of age) of the experiment in all chicken groups (challenge was performed at fourth week of age). Cross HI test results (log 2 ) using NDV genotype VII antigen at weekly interval (first to sixth weeks of age) of the experiment in all chicken groups (challenge was performed at fourth week of age). Figure 6 . IFN-gamma and IL-6 concentration "pg/ml" by ELISA at the day of challenge [28 days old (21 dpv)] in birds of G1(nonvaccinated birds), G3, G4, and G5.
Challenge Virus Shedding using rRT-PCR Tracheal and cloacal swabs collected from all birds in each group separately at 2, 6, and 9 dpc were pooled (3 sample pools or group) and revealed that viral shedding in the tracheal swabs was higher than that in cloacal swabs in all vaccinated and non-vaccinated challenged groups with peak shedding at sixth dpc in both swabs (Figure 7a and 7b) . Birds in G3, G4, and G5 showed no viral shedding at ninth dpc in the tracheal swabs, and the lowest viral shedding was observed in birds in G5 followed by those in G4 and G3. Virus shedding in cloacal swabs stopped at second dpc in birds in G5 and continued to the ninth dpc in G2 and G3; however, it appeared later at ninth dpc in G4. Neither tracheal nor cloacal viral shedding appeared in the non-challenged G1 throughout the experimental period.
DISCUSSION
One of the causes of vaccine failure in controlling NDV is antigenic variation (Maas et al., 2003) . Therefore, the question arises as to the effect of this antigenic difference in the challenge NDV virus, especially genotype VII, on protection against mortality, loss of body weight, and viral shedding in birds vaccinated with ND vaccines that contain either homologous or heterologous genotypes.
Therefore, studying the efficacy of different commercial inactivated vaccines of NDV (containing genotype Figure 7 . Viral shedding (log 10 ) in the tracheale (a) and cloacal swabs (b) at 2, 6, and 9 dpc in all experimental chicken groups.
II or VII) in protection against NDV VII challenge is critical.
All the vaccines applied in the present study did not induce protection against clinical signs or gross lesions because the respiratory signs, greenish diarrhea, and obvious PM lesions of vNDV appeared in all challenged birds irrespective of whether they were vaccinated or not from the second to the sixth dpc. Additionally, nervous signs in birds in G2 and G3 only appeared later on the eighth dpc.
Variable protection against mortality was observed because it decreased from 93.3% in G2 to 46.7%, 53.3%, and 66.7% in G4, G5, and G3, respectively, and it was obvious that the homologous vaccine containing the challenge virus was better for clinical protection than the heterologous vaccine in terms of mortality and body weight loss. The same results have been reported previously by .
However, birds in G5 showed greater protection than birds in G3 and G4 with respect to cellmediated immune response. This might be due to many factors including vaccine quality, antigenic quantity, or presence of Baculovirus and/or bivalent antigens in B.E.S.T. vaccine technology that stimulate cellular immunity, which was represented by the statistically significant (P < 0.05) cytokines (IL-6 and IFN-γ) concentrations. IFN-γ is known to be an antiviral cytokine produced by macrophages and has been proven to significantly decrease morbidity, mortality, and viral shedding induced by vNDV (Susta et al., 2013) . Moreover, IL-6 is a pro-inflammatory cytokine and stimulates B cells to produce antibodies (Kishimoto, 1989) , which might explain the higher HI antibody titer in birds of G5 than other vaccinated groups on the day of challenge.
The increased HI titer post challenge means that the vaccines did not prevent but rather reduced virus replication and shedding. This might also support the theory of the use of live (especially LaSota) plus inactivated vaccines for vNDV control, which induces a higher protection against clinical signs, mortality, and viral shedding. This is because the protective immunity against vNDV is largely directed by viral proteins involved with attachment and fusion producing antibodies or might be based on local antibodies and the humoral titer is not enough for this protection (Kapczynski ei al., 2013) .
Cross HI results support the findings of Miller et al. (2007) that HI antibody titers vary depending on the antigens used, either homologous and heterologous, during testing and differ from previous studies by (Perozo et al., 2012 ) that the genotype difference reflects on NDV behavior, but not on the antigenic arrangements or serology.
Additionally, the higher cytokines (IL-6 and IFN-γ) concentrations might explain why birds in G5 (vaccinated with heterologous genotype II vaccine) predominate G4 (vaccinated with homologous genotype VII vaccine) with respect to reduced tracheal and cloacal viral shedding, which was different than expected, as reported previously by Miller et al. (2007) . Viral shedding in tracheal swabs was higher than that in cloacal swabs in all vaccinated and non-vaccinated challenged groups, which might indicate the importance of local mucosal immunity in the respiratory tract induced by live vaccination in combination with the use of inactivated vaccines in the protection of vNDV, which was supported by (Yan et al., 2011; Kapczynski et al., 2013) .
In conclusion, the use of the homologous NDV genotype prepared inactivated vaccine induced a higher clinical protection in terms of body weight loss and mortality against vNDV VII challenge in broiler chickens; however, the heterologous vaccine used in G5 induced the highest cell mediated immune response and HI titers with the lowest viral shedding titer. The use of NDV VII as HA Ag must be applied instead of laSota Ag for higher specification of the results, especially during vNDV VII infection in chicken flocks. Finally, the consideration of dead plus live vaccination in the endemic areas with vNDV might help in the prevention of frequent outbreaks. Continuous surveillance and vaccination-protection studies for NDV must be applied to control the new generation or multiple genotypes.
